CHRONIC GOUT AND HYPERURICEMIA

TREATMENT WITH FEBUXOSTAT VERSUS ALLOPURINOL

Authors

  • Faaiz Ali Shah Mardan Medical Complex Teaching Hospital,
  • Haziqdad Khan Mardan Medical Complex Teaching Hospital
  • Kifayatullah . Mardan Medical Complex Teaching Hospital
  • Zulfiqar Ali Durrani
  • smatullah . Mardan Medical Complex Teaching Hospital
  • Zahir Khan Mardan Medical Complex Teaching Hospital

DOI:

https://doi.org/10.29309/TPMJ/2014.21.01.1789

Keywords:

Gout,, Hyperuricemia,, Febuxostat, Allopurinol.

Abstract

Objective: To assess the urate-lowering efficacy and safety of Febuxostat versus
Allopurinol in subjects with hyperuricemia and gout. Study design: Randomized controlled trial.
Place and duration of study: Department of Orthopaedic and Trauma Surgery Mardan Medical
Complex Teaching Hospital Bacha khan Medical College Mardan from February 2012 to March
2013. Material and Methods: Fifty patients of chronic gout and hyperuricemia fulfilling the
inclusion criteria were divided into two equal groups by random method having 25 patients each
and received either a fixed dose(80 mg) of Febuxostat (Group A) or Allopurinol (Group B) 300mg
once daily for 16 weeks. The primary end point was the percentage of patients reaching serum
urate level <6.0 mg/dl (360 μ mol per liter) at final visit. The secondary end points include
reduction in the incidence of gout flares and adverse drug reactions. Results: There were
16(64%) males and 9(36%) females with mean age 44.92 years in group A while group B had
15(60%) males and 10(40%) females with mean age 46.24 years. At final visit Febuxostat group
had mean uric acid level of 4.72 mg/dl ±1.56 SD while Allopurinol group had mean serum uric
acid level of 6.34 mg/dl ±1.82 SD with majority of patients (84%, n=21) in group A achieving
serum uric acid level of < 6 mg/dl (360 μmol/l) while only 60 percent (n=15) of the patients in
group B had serum urate level of < 6 mg/dl.(P= <0.05). Gout flare was reported in 12 % (n=3) of
group A patients and 36% (n=9) in group B patients. Adverse drug reactions were reported in
12% (n=3) of group A patients while 24% (n=6) in group B. Conclusions: Febuxostat lowerd
serum uric acid levels more potently than Allopurinol while having minimal gout flares and side
effects.

Author Biographies

Faaiz Ali Shah, Mardan Medical Complex Teaching Hospital,

MBBS, FCPS (Orthopaedics),
Senior Registrar
Department of Orthopaedics & Trauma

Haziqdad Khan, Mardan Medical Complex Teaching Hospital

MBBS, FCPS (Orthopaedics),
Assistant Professor
Department of Orthopaedics & Trauma,

Kifayatullah ., Mardan Medical Complex Teaching Hospital

MBBS, FCPS (Orthopaedics),
Associate Professor
Department of Orthopaedics & Trauma

Zulfiqar Ali Durrani

MBBS, MS (Orthopaedics),
District Trauma Surgeon
Department of Orthopaedics & Trauma

smatullah ., Mardan Medical Complex Teaching Hospital

MBBS, FCPS (Orthopaedics),
Professor
Department of Orthopaedics & Trauma,

Zahir Khan, Mardan Medical Complex Teaching Hospital

MBBS, FCPS (Orthopaedics),
Medical Officer
Department of Orthopaedics & Trauma,

Downloads

Published

2014-02-10